Erlotinib structure activity relationship of imatinib

Patrick: An Introduction to Medicinal Chemistry 5e - ppt video online download

erlotinib structure activity relationship of imatinib

Imatinib is a small molecule kinase inhibitor used to treat certain types of cancer. QTc prolongation can be increased when Erlotinib is combined with Imatinib. inducers, inhibitors and structure-activity relationships of human Cytochrome . Erlotinib hydrochloride (trade name Tarceva) is a drug used to treat non-small cell lung cancer, Erlotinib Structural . Some clinical studies have indicated a correlation between the severity of the As with other ATP competitive small molecule tyrosine kinase inhibitors, such as imatinib (Gleevec) in CML. *Running title: Cytochrome P 1A1 Structures. Keywords: . erlotinib (10), imatinib (11), and ponatinib structure-activity relationships.

In phase III trials involving patients with advanced non-small cell lung cancer NSCLCthe combination of bevacizumab and erlotinib as a second-line therapy resulted in prolonged produced progression-free survival PFS compared to erlotinib alone [ 13 ]. In another phase III trial for patients previously treated for advanced NSCLC, the combination of sunitinib and erlotinib produced a PFS that was significantly longer than that produced by erlotinib alone [ 14 ]. However, none of these combinations improved the OS in its respective phase III studies, and further investigation is required to improve OS.

These data support the hypothesis that concurrent inhibition of key angiokinases and the EGFR could be clinically beneficial in cancer treatment.

SAR of Parasympatholytic agents/ antimuscarinic agents/ anticholinergic agents

A phase II trial evaluating combination therapy with pazopanib and erlotinib is currently underway to corroborate this notion. While multi-targeted combination therapy is used for the treatment of a variety of advanced cancers, significant concerns exist regarding pharmacokinetics, dosing, and safety when designing such therapies [ 16 ]. Drug combinations are more most likely to cause unacceptable level of toxicity [ 1718 ].

When dose-limiting toxicities occur, each component must be administered at a less than the optimal dose, which could compromise the efficacy. In such cases, monotherapy with well-designed and carefully evaluated multi-target agents would be preferable over combination therapy. It is currently used clinically for the treatment of advanced renal cell carcinoma and soft tissue sarcoma [ 1920 ].

Erlotinib - Wikipedia

Phase II studies involving the administration of pazopanib alone and in combination with the EGFR inhibitor erlotinib are currently in progress [ 22 ]. However, we hypothesized that the modification of pazopanib to induce EGFR-inhibitory effect would lead to better treatment outcomes in patients with NSCLC and other EGFR-dependent tumors than those obtained with erlotinib or pazopanib alone.

Therefore, the pazopanib derivatives could represent promising alternatives to combination therapy. Consequently, we screened derivatives of pazopanib for multi-kinase inhibitory activities that regulate both EGFR and angiokinases. To the best of our knowledge, derivatives of pazopanib that effectively inhibit EGFR have not been reported previously. Herein, we describe the synthesis and evaluation of pyrimidine derivatives that inhibit EGFR while retaining their inhibitory activity for angiokinases, and determined their structure-activity relationship SAR.

All IC50 data were presented as the mean values.

There was a problem providing the content you requested

After a hour incubation, the cells were treated with a series of test compound dilutions for 72 hours. The cells were washed with PBS and counted in 4 random microscope fields. After overnight incubation, tubule networks were quantified by measuring the tubule length in 4 random microscope fields.

erlotinib structure activity relationship of imatinib

For the analysis of scratch wound migration, confluent cell monolayers grown on 6-well plates were scratched using a micropipette tip. Cell migration was observed by optical microscopy and quantified by measuring the number of cells that had migrated from the wound edges. The protonated and neutral states of pazopanib and its derivatives were prepared using LigPrep [ 25 ].

Patrick: An Introduction to Medicinal Chemistry 5e

Glide SP Standard-Precision was employed for flexible docking with default parameters [ 26 ]. Gefitinib Iressa Drug design Notes Fluoro substituent blocks para-hydroxylation of the aromatic ring Fluorine is similar in size to hydrogen and has no steric effect Methyl group is replaced by a chloro substituent Chlorine and methyl group have similar sizes and lipophilicities Chlorine acts as a bio-isotere for the methyl group Chlorine is resistant to oxidation Compound is less active in vitro, but more active in vivo Fluoro substiutent 14 3.

Gefitinib Iressa Drug design Notes Morpholine Spacer Ionisable Notes Morpholine ring increases water solubility Morpholine nitrogen allows generation of water soluble amine salts Spacer allows morpholine to protrude out of the active site Remains solvated when the drug is bound Avoids a desolvation penalty 15 3. Imatinib Glivec or Gleevec Notes First protein kinase inhibitor to reach the market Selective inhibitor for a hybrid tyrosine kinase Bcr-Abl Bcr-Abl is active in certain tumour cells 21 6.

erlotinib structure activity relationship of imatinib

Imatinib Glivec or Gleevec Drug design Conformational blocker Imatinib Piperazine Spacer Increased activity vs tyrosine kinases No activity against serine-threonine kinases Piperazine increases activity, selectivity and water solubility Spacer inserted to avoid aniline structure 24 6.

Imatinib Glivec or Gleevec Binding interactions Other interactions determine target selectivity A hydrogen bond to the gatekeeper Thr is essential to activity N-Alkylation eliminates activity Wiggly lines removed 26 6. Imatinib Glivec or Gleevec Binding interactions Molecular modelling studies suggest that the piperazinyl group interacts with a glutamate residue Imatinib inhibits protein kinases containing this glutamate residue Abl, c-Kit and PDGF-R Glu Ionic bond Piperazinyl group Wiggly lines removed 27 6.

Imatinib Glivec or Gleevec Binding interactions Conformational blocker aids selectivity Binds to a hydrophobic pocket that is not accessible if a larger gatekeeper residue was present Wiggly lines removed Conformational blocker 28 6.

Imatinib Glivec or Gleevec Drug resistance Mutation of the gatekeeper residue to isoleucine introduces resistance TI mutation Isoleucine unable to form an important hydrogen bond to the amine Wiggly lines removed Mutation to Isoleucine 29 6.

Login | Hematology Meeting Reports (formerly Haematologica Reports)

Imatinib Glivec or Gleevec Synthesis of imatinib and analogues 30 7. Second-generation Bcr-Abl inhibitors Notes Inhibits two protein kinase targets Abl and Src Currently in clinical trials Less likely to fall prey to drug resistance Second-generation 32 7.

Second-generation Bcr-Abl inhibitors Notes Allosteric inhibitor of Bcr-Abl Does not bind to ATP binding site Stabilises inactive form of the enzyme Binds to an autoregulatory cleft Potential agent for treating leukaemia Notes Binds to the protein substrate site Currently under study Second-generation 33 8.

erlotinib structure activity relationship of imatinib

Inhibitors of cyclin-dependent kinases CDKs are involved in control of the cell cycle and are overexpressed in many cancer cells Serine-threonine kinases Activated by cyclins Inhibited by cyclin-dependent kinase inhibitors Synthetic inhibitors bind to the ATP binding site 34 8.